Back to News
Market Impact: 0.2
Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder
Source: GlobeNewswire
Healthcare & BiotechPandemic & Health Events
Health Canada authorized a clinical trial evaluating the efficacy and safety of two MDMA-assisted therapy sessions in up to 100 veterans and frontline workers. The study is a constructive regulatory and clinical-development milestone, but it provides no efficacy results or commercial financial impact yet.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
More News
- Premarket movers: Intel jumps on SK Hynix memory-chip talks, J.B. Hunt slides
- Japan has a problematic age gap: 100,000-plus residents are over 100 and the pension system is buckling
- The MLB and its Dominican pipeline is selling false promises and shady contracts to children as young as 11
- Arrowhead Pharmaceuticals at H.C. Wainwright: launch and pipeline widen
- A healthcare provider is set up for a big move higher, according to the charts
- Scientists challenge US NIH grant screening as unconstitutional
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- What Exactly Does Post-Training in LLMs and Finance-Focused AI Actually Mean for Asset Managers?
- What Is a Financial Ontology?